Recent

% | $
Quotes you view appear here for quick access.

Chembio Diagnostics, Inc. Message Board

  • samsato18 samsato18 Jul 10, 2013 4:59 PM Flag

    BioRad CE Approval for Confirmatory DPP HIV Test

    Always good to illustrate the many other projects building momentum with DPP:

    We were also pleased to learn recently that Bio-Rad Laboratories, Inc. has received a CE Marking for the HIV 1/2 Confirmatory test which Chembio developed for and licensed to Bio-Rad, and for which Bio-Rad exercised the option to manufacture in its facility. The Bio-Rad product incorporates Chembio’s patented DPP® technology, and Chembio will receive royalty on Bio-Rad’s net sales of this product. This product was launched in Europe in April 2013, and we believe that Bio-Rad is also pursuing FDA approval of this product. As advertised, the product greatly simplifies and improves the accuracy of confirmatory testing for HIV infection, historically done using western blot technology which is less accurate, time consuming, labor intensive and complex.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Think about it. They got a confirmatory clearance. Chembio is out of that market now, as are all competitors. A POC confirmatory test trumps all.

      This is concerning. I need to hear how Chembio can capitalize on that. I also am worried about agreements on multiplex. I believe someone has rights to multiplex.

      We need to hear the benefits.

      Why did Chembio spend money on CE approval only to get trumped by their own technology?

      The great deals they made to survive may be haunting, or maybe that are great deals. I need to know.

      Yeah, Moscuba is finally concerned. Not scared, but concerned because new questions have come up that have now been proactively addressed to shareholders.

      The questions are:
      Who has the rights to DPP and what do you have to gain?
      Who has the rights to multiplex and what do you have to gain?
      What conditions are involved in the above two questions?

      This is a serious matter, at least to me.

      • 1 Reply to moscuba
      • All this is not news. It was discussed on last CC. They said they'll get a small check this Q, and growing slowly over time. I'm sure they'd rather have complete control over DPP HIV, but they don't. Still seems there should be a takeover premium in this stock. CEMI doesn't have the resources to bring DPP products to market quickly (as we've seen with Geenius). Also, CEMI us capacity constrained and distribution-limited. Were a larger company to buy CEMI, I think it's fairly clear, they could squeeze a lot more juice out of the orange.

    • Isn't that bad news? I wonder what the fees are to Chembio. I suspect far less than what they could make if the sold their product.

      I never understood that arrangement as it seems Chembio created a competitor. Then again, maybe that had to to get Biorads technology.

 
CEMI
7.25-0.02(-0.28%)3:44 PMEDT